Clinical Trials Browser

Phase 1 × INDUSTRY × Solid Tumors That Overexpress HER2 (HER2 Positive) × Clear all

NCT02286219 2017-09-18

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Phase 1 Completed

Other solid neoplasm

Solid Tumors That Overexpress HER2 (HER2 Positive)